Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

m is 0 or 1;

p is 1, 2 or 3;

G is selected from the group consisting of $-C(R^4)_2-$, -O-, -S(O)k-, wherein k is 0, 1 or 2, and $-N(R^4)-$,

A is selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H$, $-SO_3H$, $-PO(C_{1-3}alkyl)OH$ and 1*H*-tetrazol-5-yl;

each R^1 is independently selected from the group consisting of: hydrogen, halo, hydroxy, C_{1-6}alkyl and C_{1-5}alkoxy, each C_{1-6}alkyl and C_{1-5}alkoxy optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy;

R^2 is selected from the group consisting of: hydrogen, halo, hydroxy, C_{1-6}alkyl and C_{1-5}alkoxy, said C_{1-6}alkyl and C_{1-5}alkoxy optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy;

R^3 is selected from the group consisting of: hydrogen and C_{1-4}alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

or R^2 and R^3 may be joined together to form a 4, 5 or 6-membered monocyclic ring defined as follows:





or



each R^4 is independently selected from the group consisting of: hydrogen and C_{1-4}alkyl, said C_{1-4}alkyl optionally substituted from one up to the maximum number of substitutable positions with halo,

each R^5 is independently selected from the group consisting of: halo, C_{1-4}alkyl and C_{1-3}alkoxy, said C_{1-4}alkyl and C_{1-3}alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

Z is selected from the group consisting of:

(1) C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl optionally substituted with phenyl and C_{3-6}cycloalkyl, and

(2) phenyl or HET^1, each optionally substituted with 1-3 substituents independently selected from the group consisting of:

(a) halo,
(b) phenyl, optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C_{1-4}alkyl, said C_{1-4}alkyl optionally substituted with 1-3 halo groups, and
(c) C_{1-4}alkyl or C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy,

or **Z** is not present;

when **Z** is not present then **X** is selected from the group consisting of: phenyl, C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, -CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl, C_{4-15}alkoxy, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl,

when **Z** is phenyl or HET^1, optionally substituted as defined above, then **X** is selected from the group consisting of: -C_{1-6}alkyl-, -O-C_{1-5}alkyl-, -(C=O)-C_{1-5}alkyl-, -(C=O)-O-C_{1-4}alkyl-, -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl-,



, phenyl and HET^2, said phenyl and HET^2 each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4}alkyl and C_{1-4}alkoxy, and wherein when **X** is -C_{1-6}alkyl-, -O-C_{1-5}alkyl-, -(C=O)-C_{1-5}alkyl-, -(C=O)-O-C_{1-4}alkyl-, -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl-, or



, the point of attachment of the group **Z** is on the alkyl,

and

when **Z** is C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl, optionally substituted as defined above, then **X** is phenyl, said phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4}alkyl and C_{1-4}alkoxy;

R^6 and R^7 are independently selected from the group consisting of: hydrogen, C_{1-9}alkyl and -$(CH_2)_p$-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C_{1-3}alkyl and C_{1-3}alkoxy, each optionally substituted with 1-3 halo groups; and

HET^1 and HET^2 are each independently selected from the group consisting of: benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl.

2. (original) The compound according to Claim 1 wherein p is 1.

3. (original) The compound according to Claim 1 wherein:

Z is phenyl or HET^1, each optionally substituted with 1-3 substituents independently selected from the group consisting of:

(a) halo,
(b) phenyl, optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C_{1-4}alkyl, said C_{1-4}alkyl optionally substituted with 1-3 halo groups, and
(c) C_{1-4}alkyl or C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy,

or **Z** is not present;

when **Z** is not present then **X** is selected from the group consisting of: C_{7-12}alkyl, C_{7-12}alkenyl, C_{7-12}alkynyl, C_{6-11}alkoxy, -O-C_{6-11}alkenyl, -O-C_{6-11}alkynyl, -(C=O)-C_{6-11}alkyl, -(C=O)-C_{6-11}alkenyl, -(C=O)-C_{6-11}alkynyl, -(C=O)-O-C_{5-10}alkyl, -(C=O)-O-C_{5-19}alkenyl, and -(C=O)-O-C_{5-10}alkynyl;

and

when **Z** is phenyl or HET^1, optionally substituted as defined above, then **X** is selected from the group consisting of -C_{1-5}alkyl-, -C_{1-4}alkoxy-, -(C=O)-C_{1-4}alkyl-, -(C=O)-O-C_{1-3}alkyl-, phenyl and HET^2, and wherein when **X** is -C_{1-4}alkoxy-, -(C=O)-C_{1-5}alkyl- or -(C=O)-O-C_{1-4}alkyl-, the point of attachment of the group **Z** is on the alkyl.

4. (original) The compound according to Claim 1 wherein HET^1 and HET^2 are indepedently selected from the group consisting of:



wherein R^8 is selected from hydrogen, hydroxy and halo.

5 to 6. (canceled)

7. (original) The compound according to Claim 1 wherein **X** is selected from the group consisting of: C_{7-12}alkyl, C_{7-12}alkenyl, C_{7-12}alkynyl, C_{6-11}alkoxy, -O-C_{6-}

$_{11}$alkenyl, -O-C_{6-11}alkynyl, -(C=O)-C_{6-11}alkyl, -(C=O)-C_{6-11}alkenyl, -(C=O)-C_{6-11}alkynyl, -(C=O)-O-C_{5-10}alkyl, -(C=O)-O-C_{5-19}alkenyl, and -(C=O)-O-C_{5-10}alkynyl and **Z** is not present.

8. (original) The compound according to Claim 1 wherein:

X is methoxy and **Z** is HET^1 substituted with phenyl and C_{1-4}alkyl, said C_{1-4}alkyl optionally substituted with 1-3 halo groups, and said phenyl optionally substituted with 1 to 5 substituents independently selected from the group conisting of: halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups.

9. (canceled)

10. (original) The compound according to Claim 1 wherein:

X is HET^2, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4}alkyl and C_{1-4}alkoxy, and

Z is phenyl or HET^1, each optionally substituted with 1-3 substituents independently selected from the group consisting of:

(a) halo,
(b) phenyl, optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C_{1-4}alkyl, said C_{1-4}alkyl optionally substituted with 1-3 halo groups, and
(c) C_{1-4}alkyl or C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy.

11 to 12. (canceled)

13. (original) The compound according to Claim 1 wherein:

Z is C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl optionally substituted with phenyl and C_{3-6}cycloalkyl, and

X is phenyl, said phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4}alkyl and C_{1-4}alkoxy.

14. (original) The compound according to Claim 1 wherein **G** is –CH_2-.

15. (canceled)

16. (original) The compound according to Claim 1 wherein R^2 and R^3 are not joined together to form a ring.

17. (original) The compound according to Claim 1 wherein R^2 and R^3 are joined together to form a 4-membered monocyclic ring defined as follows:



18. (original) The compound according to Claim 1 wherein R^2 and R^3 are joined together to form a 5-membered monocyclic ring defined as follows:



19. (canceled)

20. (original) A compound according to Claim 1 of Formula II:



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein n is 0 or 1.

21. (original) The compound according to Claim 20 wherein n is 0 and –**X**-**Z** is selected from the following group:



22. (original) The compound according to Claim 20 of Formula III



III

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n is 0 or 1,

Y is oxygen or a bond,

R^{10} is C_{1-4}alkyl,

each R^9 is independently halo, C_{1-4}alkyl or C_{1-4}alkoxy.

23. (currently amended) The compound according to ~~Claim 21~~ Claim 22 wherein n is 0, each R^4 is hydrogen and R^5 and R^9 are both not present.

24. (original) A compound or a pharmaceutically acceptable salt thereof selected from the following table:




F
F
F
S
O
N
O
OH
F
F
F
S
O
N
N
O
OH
F
F
F
S
O
NH
N
N
N
F
F
F
S
O
NH
OH
O


F
F
F
S
O
NH
O
OH
O
OH
N
O
S
F
F
F
O
OH
N
O
S
F
F
F
OH
O
N
O


O
OH
N
O
O
N
O
OH
O
N
N
O
OH
O
N
N
O
OH



25. (original) A compound selected from the following:

(1) (RS)-1-(5-(5-(4-(2-Methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl)azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof,

(2) (R)-1-(5-(5-(4-(2-Methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl)azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and

(3) (S)-1-(5-(5-(4-(2-Methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl)azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

26. (original) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

27 to 39. (canceled)

40. (original) A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.

41 to 42. (canceled)